Pfizer Corporation

Other

Warner-lambert Company

Barbara A Johnson

Richard W Korsmeyer

Ernest Quan

Cynthia A Oksanen

Michael Robert Johnson

Michael B Fergione

Clifford B Johnson, Jr

Williane Amadio

Kenneth Craig Waterman

Alex Amadio

Brendan Murphy

Steven W Collier

Clip

A support rod storage securing system includes a container for holding clothing that has a bottom wall and a perimeter wall that is attached to and extending upwardly from the bottom wall. The perimeter wall has an upper edge defining an opening extending into the container. A frame member is mounted to the container. A collapsible dressing station is removably mountable to the container such that the collapsible dressing station extends upwardly from the container. The collapsible dressing station includes an upper bar configured to receive clothes hangers. A pair of connectors each is attached to the frame member. The upper bar is removably mounted on the pair of connectors such that the upper bar is releasably retained in a static position within the container.

Support rod storage securing system

A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.

Pharmaceutical compositions of atorvastatin

This invention relates to a pharmaceutical formulation, in the form of a tablet, sachet or powder for suspension dosage form, which comprises dry granulated particles of a non-dihydrate form of azithromycin and, optionally, one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical formulation is a tablet containing between about 40%, by weight, to about 90%, by weight, non-dihydrate azithromycin. More preferably, the pharmaceutical formulation contains non-dihydrate azithromycin selected from the forms B, D, E, F, G, H, J, M, N, O, P, Q, R, or mixtures thereof. Even more preferably, the invention relates to a pharmaceutical formulation wherein the dosage of azithromycin is 250 mgA, 500 mgA, 600 mgA or 1000 mgA. The present invention further relates to a dry granulated azithromycin particle, comprising a form of azithromycin, selected from forms D, E, F, G, H, J, M, N, O, P, Q, R and mixtures of non-dihydrate forms, and at least one pharmaceutically acceptable excipient.

Dry granulated formulations of azithromycin

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Directly compressible formulations of azithromycin

A dosage form containing cetirizine as an immediate release component and pseudoephedrine or a pharmaceutically acceptable salt thereof as a controlled release component. A portion of the pseudoephedrine can also be incorporated as an immediate release component. The dosage form is free of alcohols having a molecular weight lower than 100 and reactive derivatives thereof.

Combination dosage form comprising cetirizine and pseudoephedrine

A fly swatter device is set forth wherein housing formed with an open upper end telescopingly receives a slide member interiorly thereof. The slide member is latched in a lower first position and extended to a second telescoping position. An array of striker slats is pivotally mounted to an axle orthogonally directed through opposed walls of the slide member utilizing an elastomeric cord to expand the slats to a splayed orientation upon the slide member extending to the second position.

Fly swatter device

This invention provides a urine leg drainage bag supporter comprising a waist encircling belt; a pouch for holding a urine bag, the pouch being formed of front and back panels connected at the vertical edges to define an opening in the top and bottom portions of the pouch, the front panel being formed of a stretchable material to firmly hold the bag within the pouch; a plurality of vertical straps connecting the pouch to the belt; and a plurality of horizontal straps extending from the pouch for encircling the leg of the wearer.

Growing community of inventors

Niantic, CT, United States of America

Barbara A Johnson